KRASi is moving into neoadjuvant treatment of pancreatic cancer and showed promising results in different combinations: #ESMO26 KRAS G12Di inhibitor HRS-4642 combined with chemo, IO, or anti-EGFR trials in China. More options for pancreatic patients are coming.